Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL5604919 | 1.00 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL5604901 | 1.00 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL2589315 | 1.00 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL161673 | 1.00 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL4363333 | 0.98 | CA1 (0.46) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL2826637 | 0.98 | CA1 (0.46) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL2826645 | 0.98 | CA1 (0.46) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL4364490 | 0.98 | CA1 (0.46) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL10427322 | 0.98 | CA1 (0.46) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL23611029 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| US-20240041919-A1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC | 2024-02-08 | — | — | US | claimed |
| US-11801261-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2023-10-31 | — | — | US | claimed |
| CN-115414265-A | Composition and face cream with effects of color correction, skin tendering and moisturizing and preparation method thereof | 中国科学院过程工程研究所 | 2022-12-02 | — | — | CN | claimed |
| US-20220323485-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | PIKE, JOSEPH D. | 2022-10-13 | — | — | US | claimed |
| EP-2827847-B1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-09-14 | — | — | EP | claimed |
| EP-3284462-B1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220054535-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | STRONTIUM NEUROGENICS INC (US) | 2022-02-24 | — | — | US | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005108339-A2 | HIGH YIELD AND RAPID SYNTHESES METHODS FOR PRODUCING METALLO-ORGANIC SALTS | OSTEOLOGIX A/S (DK) | 2005-11-17 | — | — | WO | claimed |
| WO-2005082385-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2005-09-09 | — | — | WO | claimed |
| EP-1534305-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | Osteologix A/S (DK) | 2005-06-01 | — | — | EP | claimed |
| WO-2004098619-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098618-A2 | STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| EP-0416321-B1 | Crystalline polyolefin composition | CHISSO CORP (JP) | 1994-11-09 | — | — | EP | claimed |
| US-5063264-A | Molding materials | CHISSO CORPORATION (JP) | 1991-11-05 | — | — | US | claimed |
| EP-0416321-A1 | Crystalline polyolefin composition | Chisso Corporation (JP) | 1991-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | SUCNR1, TRPV1, TRPV2 | CA1 208/4885BBOX1 1932/4885GRM8 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.